Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Election/Restrictions
Claims 1-5 are pending.
Applicant’s election without traverse of Group I, claims 1-3, in the reply filed on 1/26/26 is acknowledged.
Claims 4-5 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 1/26/26.
Claims 1-3 are examined on the merits.
Claim Objections
Claim 3 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Claim Rejections –35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-2 are rejected under 35 U.S.C. 102 (a)(1) as being anticipated by De Witte et al (US 9782361) (see IDS filed on 5/2/25).
De Witte et al teach a method for treating convulsive disorders of the central nervous system (thus a method for treating non-neurodegenerative disease, thus claim 1 is met) comprising administering to a subject in need thereof an effective amount of an anticonvulsant therapeutic agent consisting of one or more bisabolene sesquiterpenoids of turmeric essential oil (thus the claimed turmeric oil) (see claim 1). The method of claim 1 wherein the turmeric essential oil is obtained from a Curcuma genus (see claim 2). The method of claim 1 wherein the convulsive disorders of the central nervous system include epileptic seizures, symptoms associated with epileptic seizures, seizure-like behaviors, epilepsy, and tremor (see claim 5). De Witte et al teach a first aspect of the present invention relates to a bisabolene sesquiterpenoid for use as an anticonvulsant agent in disorders of the central nervous system. In some embodiments, the present invention relates to a bisabolene sesquiterpenoid of turmeric oil for use as an anticonvulsant agent in disorders of the central nervous system. The turmeric oil may be from a Curcuma genus in particular Curcuma longa L. (thus claim 2 is met) (col 3, lines 16-24).
Therefore, the reference is deemed to anticipate the instant claim above.
Conclusion
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to QIUWEN MI whose telephone number is (571)272-5984. The examiner can normally be reached on Monday-Friday 9:00 am to 5:00 pm.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Qiuwen Mi/
Primary Examiner, Art Unit 1655